Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.
Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP. Hollebecque A, et al. Among authors: paci a. Eur J Cancer. 2017 Aug;81:81-89. doi: 10.1016/j.ejca.2017.05.021. Epub 2017 Jun 12. Eur J Cancer. 2017. PMID: 28618305 Clinical Trial.
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
Rubie H, Geoerger B, Frappaz D, Schmitt A, Leblond P, Ndiaye A, Aerts I, Le Deley MC, Gentet JC, Paci A, Chastagner P, Dias N, Djafari L, Pasquet M, Chatelut E, Landman-Parker J, Corradini N, Vassal G. Rubie H, et al. Among authors: paci a. Eur J Cancer. 2010 Oct;46(15):2763-70. doi: 10.1016/j.ejca.2010.05.004. Epub 2010 Jun 16. Eur J Cancer. 2010. PMID: 20558056 Clinical Trial.
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
Mauclère-Denost S, Leboulleux S, Borget I, Paci A, Young J, Al Ghuzlan A, Deandreis D, Drouard L, Tabarin A, Chanson P, Schlumberger M, Baudin E. Mauclère-Denost S, et al. Among authors: paci a. Eur J Endocrinol. 2012 Feb;166(2):261-8. doi: 10.1530/EJE-11-0557. Epub 2011 Nov 2. Eur J Endocrinol. 2012. PMID: 22048971 Clinical Trial.
Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study.
Bonvalot S, de Baere T, Mendiboure J, Paci A, Farace F, Drouard-Troalen L, Bonnet L, Hakime A, Bonniaud G, Raynard B, Israel P, Le Cesne A, Eggermont AM, Laplanche A, Muret J. Bonvalot S, et al. Among authors: paci a. Ann Surg. 2012 Feb;255(2):281-6. doi: 10.1097/SLA.0b013e318242ebe7. Ann Surg. 2012. PMID: 22241290 Clinical Trial.
Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE).
Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N, Schmitt C, Tabone MD, Blouin P, Sirvent N, Goma G, Geoerger B, Oberlin O. Minard-Colin V, et al. Among authors: paci a. Eur J Cancer. 2012 Oct;48(15):2409-16. doi: 10.1016/j.ejca.2012.04.012. Epub 2012 May 25. Eur J Cancer. 2012. PMID: 22633624 Clinical Trial.
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, Zitvogel L, Chaput N, Paci A. Pautier P, et al. Among authors: paci a. Oncoimmunology. 2013 Feb 1;2(2):e23079. doi: 10.4161/onci.23079. Oncoimmunology. 2013. PMID: 23525192 Free PMC article.
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.
Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, Paci A, Rosenzwajg M, Klatzmann D, Eggermont A, Robert C, Zitvogel L. Chaput N, et al. Among authors: paci a. Oncoimmunology. 2013 Feb 1;2(2):e23080. doi: 10.4161/onci.23080. Oncoimmunology. 2013. PMID: 23525357 Free PMC article.
323 results